KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-cash Items: 2018-2020

Historic Non-cash Items for Esperion Therapeutics (ESPR) over the last 2 years, with Jun 2020 value amounting to $3.2 million.

  • Esperion Therapeutics' Non-cash Items rose 3.17% to $3.2 million in Q2 2020 from the same period last year, while for Jun 2020 it was $3.2 million, marking a year-over-year increase of 3.17%. This contributed to the annual value of $109.1 million for FY2019, which is 30.65% up from last year.
  • Per Esperion Therapeutics' latest filing, its Non-cash Items stood at $3.2 million for Q2 2020, which was up 1.09% from $3.2 million recorded in Q1 2020.
  • In the past 5 years, Esperion Therapeutics' Non-cash Items ranged from a high of $109.1 million in Q4 2019 and a low of $2.3 million during Q1 2018.
  • Over the past 3 years, Esperion Therapeutics' median Non-cash Items value was $3.2 million (recorded in 2020), while the average stood at $33.4 million.
  • Data for Esperion Therapeutics' Non-cash Items shows a peak YoY increase of 30.65% (in 2019) and a maximum YoY decrease of 42.30% (in 2019) over the last 5 years.
  • Quarterly analysis of 3 years shows Esperion Therapeutics' Non-cash Items stood at $83.5 million in 2018, then soared by 30.65% to $109.1 million in 2019, then rose by 3.17% to $3.2 million in 2020.
  • Its Non-cash Items was $3.2 million in Q2 2020, compared to $3.2 million in Q1 2020 and $109.1 million in Q4 2019.